# Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis

> **NCT07746518** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 420 (estimated)

## Conditions studied

- Healed Erosive Esophagitis

## Interventions

- **DRUG:** DWP14012 20mg
- **DRUG:** DWP14012 20 mg placebo
- **DRUG:** DWC202517 15 mg
- **DRUG:** DWC202517 15 mg placebo

## Key facts

- **NCT ID:** NCT07746518
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-08
- **Final completion:** 2030-03
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746518, "Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*